New trials in relapsed high-grade lymphomas

Graham Collins

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses new clinical trials in relapsed high-grade lymphomas at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about a planned trial of the PD-1 inhibitor nivolumab as a bridge to stem cell transplantation in relapsed Hodgkin Lymphoma. In high-grade lymphoma, Dr Collins is running the TORCH trial (NCT02752204) of the next-generation mTOR inhibitor vistuserib in relapsed diffuse large B-cell lymphoma. He also highlights the potential of rational combination therapies in relapsed high-grade lymphomas.

Share this video  
Similar topics
Related videos
1:38
Future of aggressive lymphoma treatment: a shift towards chemo-free regimens
Raúl Córdoba
2:28
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Marek Trneny
2:36
Hodgkin lymphoma: difficulties faced in geriatrics
Wendy Osborne
2:38
CAR T-cells improve response and CR rates in R/R DLBCL
Christian Gisselbrecht
3:02
New technologies informing SOC in DLBCL
Christian Gisselbrecht
Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma
Checkpoint Inhibitors, Nivolumab, Vistusertib
TORCH
BSH 2017
Interview
27th March 2017
More from Graham Collins
CAR-T cell therapy debate: the future of lymphoma treatment?
Revolutionary immunotherapy for lymphoma
BSH 2017 lymphoma highlights: looking at synergies between immuno-oncology agents
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals